News | Atrial Fibrillation | July 12, 2017

Wearable Cardiac Monitors Are Effective for Tracking Atrial Fibrillation Following Ablation

Cardea Solo wearable cardiac monitor eliminates service centers and put control of patient data, analysis in the hands of doctors

Cardiac Insight FDA-approved Cardea Solo wearable ECG monitoring system

July 12, 2017 — Cardiac Insight Inc., a U.S. developer of wearable medical devices and diagnostic software, announced its FDA-approved Cardea Solo ECG monitoring system is available for diagnosing atrial fibrillation (AF or AFib) following cardiac ablation. The company’s cardiac monitoring device supports a recent formal consensus statement by experts from 11 leading international cardiology organizations that recognizes the use of wearable sensing devices in patients who have undergone AFib ablation procedures.

The formal acknowledgement of wearable sensors was one of a series of recommendations for treating the millions of patients who have AF, a common rhythm disorder that increases the risk of heart failure and stroke. The expert consensus statement was collectively developed by the Heart Rhythm Society (HRS), European Heart Rhythm Association, European Cardiac Arrhythmia Society, among several others.

Cardiac ablation is an invasive procedure that is used to eliminate atrial fibrillation. Among its many applications, Cardea Solo is a new, distinctive, cost-effective and timely solution for monitoring the effectiveness and results of atrial fibrillation ablation.

“The societies’ recommendations will advance the treatment of atrial fibrillation, including the use of wearable sensors like Cardea Solo for diagnosing heart rhythm disorders and monitoring patients after atrial fibrillation ablation,” said Robert Hauser, M.D., FACC, FHRS, HRS past-president and senior consulting cardiologist (retired), Minneapolis Heart Institute. “It is vital to detect and treat atrial fibrillation before it causes a stroke or heart failure. Cardea Solo provides the information doctors need in a more timely and cost-effective manner than currently offered by other wearable sensors.”

Cardea Solo is the first and only wearable cardiac sensor to eliminate the need for expensive and time-consuming third-party service centers and puts the control of patient data, analysis and processing in the hands of physicians and their staffs.

The device sensor records ECG data and patient symptoms. The wearable sensor is small, lightweight (approximately the weight of three quarters), lead-less, water-resistant and single-use disposable. Patients can wear Cardea Solo comfortably under their clothing for up to seven days and maintain their normal daily activities. The design and ease-of-use also makes it more likely patients will wear the sensor and capture meaningful data for enhanced evaluation.

For more information: www.cardiacinsightinc.com

Related Content

PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking
Contact Force Sensing Catheter Improved Outcomes in Persistent Atrial Fibrillation Ablation. #HRS2020 #heartrhythm2020
News | Atrial Fibrillation | May 13, 2020
May 13, 2020 — The PRECEPT study testing the use of the Biosense Webster Thermocool Smarttouch SF Catheter for the tr
The Swiss-AF study shows High Incidence Of Silent Brain Infarcts Found in Anticoagulated Atrial Fibrillation Patients. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 – A new clinical study found that patients with...
PINNACLE FLX Study of New Watchman FLX LAA Occluder Meets Safety and Efficacy Endpoints. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — Positive 12-month results were announced today from the...
The first-in-human results show positive results for Medtronic's pulsed field ablation in safety and efficiency. #Heartrhythm2020 #HRS2020 #HRS20
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — New clinical trial reveals the first-in-human results for paroxysmal or persistent atrial fibrillation
POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation  (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
News | Atrial Fibrillation | March 29, 2020
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing transcath
Medtronic's PulseSelect Pulsed Field Ablation (PFA) System

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System.

News | Atrial Fibrillation | January 31, 2020
January 31, 2020 – The U.S.
Frequent Drinking Greater Risk Factor for Heart Rhythm Disorder Than Binge Drinking

Image courtesy of the American Heart Association.

News | Atrial Fibrillation | October 22, 2019
October 22, 2019 —  Drinking small amounts of alcohol frequently is linked with a higher likelihood of...